Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
4/17/18: Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints. Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval
Novocure’s Optune Now Available at More Than 600 Cancer Treatment Centers in the U.S.
Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system for the treatment of GBM.
First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma (GBM).
Optune is an FDA-approved Tumor Treating...
Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma
May 15, 2017
Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma.
Novocure states the...
Martin J. Madden Joins Novocure Board of Directors
The company said that Mr. Madden recently retired after a 30-year career in medical device innovation at Johnson & Johnson but recently served as Vice President, Research and Development DePuy-Synthes and Vice President Medical Device R&D Transformation
Novocure...
